Cordis has received CE mark approval to market the Cypher Select plus Sirolimus-eluting coronary stent for the treatment of acute myocardial infarction, more commonly known as a heart attack.

CE mark approval means that the product has been deemed safe and effective for the treatment of acute myocardial infarction and can now be promoted for this indication in all member states of the European Union (EU), European Economic Area and Switzerland.

The expanded indication for the Cypher Select plus stent in the EU is based on several scientific publications providing clinical evidence for this indication, especially data from Typhoon, the first randomized, multi-center clinical trial to study the safety and efficacy of the Cypher stent in patients who suffered a heart attack, said Cordis.

In Typhoon, the Cypher stent reduced the risk of target vessel failure by almost half in patients who suffered a heart attack compared to those who were treated with a bare metal stent, according to Cordis.